Viridian Therapeutics is a biotechnology company. Co. is developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED), an auto-immune disease that causes inflammation and fibrosis of the orbit and tissues surrounding the eye which can lead to proptosis, or bulging of the eyes, redness and swelling, double vision, pain, and potential blindness. Co.'s primary program, VRDN-001, is a humanized monoclonal anti-insulin-like growth factor-1R (anti-IGF-1R) antibody that Co. has licensed from ImmunoGen, Inc. Co. is also developing VRDN-002, an IGF-1R monoclonal antibody, for TED. The VRDN stock yearly return is shown above.
The yearly return on the VRDN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the VRDN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|